Immunotherapy Agents in Pancreatic Cancer
Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the potential for immunotherapies in pancreatic cancer.
Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the potential for immunotherapies in pancreatic cancer.
Clinical Pearls:
- Developing immunotherapy agents in this space is a work in progress
- Investigators at Johns Hopkins University School of Medicine have been looking at an autologous cell-based vaccine
- Antigen-specific vaccines are also in development for pancreatic cancer
- There is a need to “make room†for immunotherapies and determine their optimal use, especially with regard to immune checkpoint inhibitors, such as PD-1 and anti-CTLA-4
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
